Phage therapy: delivering on the promise

Area of Science:

• Microbiology
• Virology
• Therapeutics

Background:

• Bacteriophages (phages) are viruses that infect bacteria.
• Phage therapy, using phages to treat bacterial infections, was explored early but largely replaced by antibiotics.
• Antibiotic resistance has renewed interest in phage therapy, necessitating rigorous clinical trials.

Purpose of the Study:

• To review the history and current status of phage therapy.
• To highlight the potential of bacteriophages as therapeutics in the context of antibiotic resistance.
• To discuss the challenges and prospects of developing phage therapy for regulatory approval.

Main Methods:

• Historical review of phage therapy research and clinical applications.
• Analysis of early clinical trial data and reasons for limited success.
• Examination of recent clinical trial progress, including Phase I and Phase II studies.

Main Results:

• Early phage therapy efforts were hampered by a lack of understanding and inconsistent results.
• Recent clinical trials (Phase I safety in 2005, Phase II efficacy in 2009) demonstrate progress in developing phage therapeutics.
• Bacteriophages possess unique properties, such as self-replication at infection sites, offering advantages over conventional antibiotics.

Conclusions:

• Phage therapy is a viable therapeutic strategy for combating bacterial infections, particularly in the era of antibiotic resistance.
• Overcoming challenges in delivery and standardization is crucial for regulatory approval (e.g., by the European Medicines Agency and US FDA).
• The self-replicating nature of bacteriophages at the site of infection presents a significant therapeutic advantage.